Biotech: Page 2


  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Startup Mariana raises $175M for radiopharmaceutical drug research

    The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.

    By Sept. 7, 2023
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen, continuing executive revamp, finds a new research head

    Jane Grogan, an industry veteran who worked at Genentech for over 15 years, will take over the role starting Oct. 2. She’ll fill a seat that's lacked a permanent replacement since the departure of Al Sandrock.

    By Sept. 6, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • J&J sends blood pressure drug back to Idorsia

    The decision is the latest in a series of setbacks for the Actelion spinout and ends a lucrative partnership that began in 2017.

    By Kristin Jensen • Sept. 6, 2023
  • Portrait of Jeb Keiper, CEO of Nimbus Therapeutics.
    Image attribution tooltip
    Permission granted by Nimbus Therapeutics
    Image attribution tooltip

    Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise

    The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively.

    By Sept. 6, 2023
  • peanuts
    Image attribution tooltip
    Christopher Doering/BioPharma Dive
    Image attribution tooltip

    Nestle gives up on peanut allergy treatment after sluggish sales

    The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

    By Sept. 5, 2023
  • The star Vega shines brightly in the night sky, surrounded by other stars.
    Image attribution tooltip
    Franco Tognarini via Getty Images
    Image attribution tooltip

    Star Therapeutics adds another $90M to grow its galaxy of drug startups

    The hub-and-spoke biotech has raised more than $190 million in total to fund drug development for rare autoimmune and blood conditions.

    By Sept. 5, 2023
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    FDA documents hint at ‘uphill battle’ for broad approval of Sage’s depression drug

    The newly posted documents show the agency had concerns about the side effects experienced by people with clinical depression who took Sage’s drug, Zurzuvae.

    By Sept. 1, 2023
  • An empty laboratory
    Image attribution tooltip
    onurdongel via Getty Images
    Image attribution tooltip

    Sage, reeling from depression drug decision, to lay off 40% of workforce

    Two founding executives are leaving Sage alongside a major restructuring announced weeks after the FDA approved the medicine, Zurzuvae, for much narrower use than the company had hoped.

    By Kristin Jensen • Aug. 31, 2023
  • A close-up shot of a woman's hands, handling a syringe of insulin.
    Image attribution tooltip
    ClarkandCompany via Getty Images
    Image attribution tooltip

    Intarcia, a former biotech unicorn, gets new life with startup deal

    I2o Therapeutics, now led by former Intarcia head Kurt Graves, licensed the diabetes treatment Intarcia has spent more than a decade developing.

    By Aug. 30, 2023
  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo, continuing deal streak, buys another obesity drug startup

    The acquisition of Embark Biotech, which Novo helped found, gives the company another prospect to add to its arsenal of weight-loss medicines.

    By Aug. 30, 2023
  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Jose Luis Calvo Martin, Jose Enrique Garcia-Maurino Muzquiz via Getty Images
    Image attribution tooltip

    FibroGen’s Duchenne drug fails second trial in latest study setback

    The failure marks another Phase 3 miss for the drug, pamrevlumab, and follows a restructuring and CEO switch for the struggling biotech.

    By Aug. 30, 2023
  • Free photo dna closely
    Image attribution tooltip

    freepik.com/kjpargeter

    Image attribution tooltip

    Epigenic joins wave of startups raising cash to edit the epigenome

    The China-based company is one of at least four young biotechs in a competitive race to use CRISPR tools to alter gene expression without changing DNA.

    By Kristin Jensen • Aug. 30, 2023
  • A photo of a sign inside an Apellis Pharmaceuticals building
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis to lay off 25% of staff, trim research in major restructuring

    The job cuts will affect about 225 employees, making it one of the largest single rounds of layoffs within the biotech sector this year.

    By Aug. 29, 2023
  • An illustration of dopamine outside the cell binding to a receptor.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt

    GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

    By Aug. 28, 2023
  • Bayer reports positive early data for Parkinson’s cell therapy

    The treatment, developed by a biotech Bayer acquired in 2019, appeared safe in a small trial and showed signs of an effect on disease progression. 

    By Aug. 28, 2023
  • Futuristic Medical Research Laboratory: Research Scientist Wearing Virtual Reality Headset, Does Augmented Reality Research of Bacteria Genome,
    Image attribution tooltip
    gorodenkoff via Getty Images
    Image attribution tooltip
    Sponsored by Cognizant

    Artificial intelligence: The prime mover in drug discovery

    With its ability to process vast amounts of data and identify patterns, AI can significantly reduce the time and cost involved in developing new drugs.

    Aug. 28, 2023
  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip
    Emerging biotech

    Neumora, a richly funded brain drug developer, readies for an IPO

    Neumora’s filing, along with that of radiopharmaceutical startup RayzeBio last week, could be an important test of the biotech IPO market.

    By Aug. 25, 2023
  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    JaysonPhotography via Getty Images
    Image attribution tooltip

    Radiopharmaceutical drugmaker RayzeBio signals plans to go public

    Biotech's IPO drought has endured into late August, but a small group of drugmakers are now in line ahead of a fall that analysts predict could be busier.

    By Aug. 25, 2023
  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    Agenus to lay off 25% of staff, trim pipeline in cancer drug push

    The job cuts are meant to preserve enough cash so the nearly three-decade-old company can potentially pursue its first drug approval next year.

    By Aug. 23, 2023
  • A 3D visualization of neurons and neural network with signals.
    Image attribution tooltip
    Evgenii Kovalev via Getty Images
    Image attribution tooltip

    J&J-backed startup raises another $150M for brain drug development

    The funding for Rapport Therapeutics saw participation from a series of so-called crossover investors, many of which have pulled back from biotech startups in recent years. 

    By Aug. 23, 2023
  • An image of Apellis Pharmaceuticals' vision loss drug Syfovre
    Image attribution tooltip
    Courtesy of Apellis Pharmaceuticals
    Image attribution tooltip

    Apellis finds faulty needles in probe of rare eye drug side effects

    The company doesn’t know if the needles have caused retinal vasculitis in some people receiving its geographic atrophy drug Syfovre, but is no longer recommending their use.

    By Kristin Jensen • Aug. 23, 2023
  • Colorized scanning electron micrograph of a cell heavily infected with SARS-CoV-2 virus particles, isolated from a patient sample
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    ‘Project NextGen’ to spend $1.4B in search for better COVID drugs, vaccines

    The funds going to Regeneron, clinical trial partners and other developers are the first major investments under a federal program announced in May.

    By Aug. 22, 2023
  • A 3D illustration of sickle cell anemia disease blood cells
    Image attribution tooltip
    Stock/Ezume Images via Getty Images
    Image attribution tooltip

    Fulcrum rejoins sickle cell drug race as FDA lifts study hold

    The biotech, which aims to develop an alternative to existing medicines and emerging gene-based treatments, will focus further testing on sicker patients.

    By Aug. 22, 2023
  • Michel Streuli, Max Krummel and Venkataraman Sriram, co-founders of Foundery, pictured from left to right.
    Image attribution tooltip
    Permission granted by Foundery
    Image attribution tooltip
    Emerging biotech

    Foundery, a new biotech venture firm, sets out to speed early immune drug research

    Billing itself as both a scientific and investment partner, Foundery aims to provide drug development support to researchers working on new immunotherapies.

    By Aug. 22, 2023
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    FDA expands use of Neurocrine drug to Huntington’s patients

    Analysts expect the approval of Ingrezza in Huntington’s patients with a movement disorder known as chorea to intensify a commercial battle between Neurocrine and Teva.

    By Aug. 21, 2023